The Oxford Participation and Activities Questionnaire (OxPAQ) – Minimal Important Differences (MID) and effect sizes are now available!
Minimal Important Difference (MID) and Effect Sizes for the measure’s domains now available
Minimal Important Difference (MID) and Effect Sizes for the measure’s domains now available
Oxford University Innovation's Clinical Outcome team will be attending the annual PROMS research conference in Leeds, UK on the 13th June 2019.
Oxford University Innovation's Clinical Outcome team will be attending the annual ISPOR conference in New Orleans, LA from the 18th - 22nd May 2019.
The Clinical Outcomes team at Oxford University Innovation are very pleased to announce the availability of diabetes-specific preference-based measures that can be used to produce valuable health economic data.
The OxPAQ is now validated for use in Chronic obstructive pulmonary disease (COPD), Aneurysmal subarachnoid haemorrhage (AHS) and Valvular heart disease.
Clinical Outcomes will be promoting some new additions to their portfolio of diabetes outcome measures at ATTD in Berlin, Germany, 20th -23rd February!
The Oxford Cognitive Screen, a stroke-specific screening test, is now available in Danish and an alternative to the MoCA.
In addition to the original Ox-PAQ, an acute version is now available which asks participants to recall their experiences during a much shorter time period of 1 week, rather than 4.
The Clinical Outcome team will be attending the first national ReQoL in Practice event in Sheffield, UK on the 29th November 2018.
With over 10 million people currently living with arthritis, Versus Arthritis (formerly Arthritis Research UK) pushes to defy the disease!